Predict the stock price of TNXP tomorrow?

``` The deep research logic is organized as follows: Okay, let's tackle the user's question about predicting TNXP's stock price tomorrow. First, I need to gather all the relevant data from the provided references. The user is asking for a prediction, so I should focus on recent news, market movements, and any upcoming events that could impact the stock price. Looking at the references, TNXP is Tonix Pharmaceuticals, and there's a lot of recent activity. The FDA decision for their fibromyalgia drug, TNX-102 SL, is pending with a PDUFA date on August 15, 2025 . That's a critical event because FDA approvals can cause significant stock price movements. The company also recently got included in the Russell 2000 and 3000 indexes , which could bring in passive fund inflows and increase visibility. The stock price as of the last data point is $47.19 with a 4.73% increase . Recent news includes positive Phase 3 trial results for TNX-102 SL published in Pain Medicine , which is a strong positive signal. Additionally, they presented promising data on their mpox vaccine TNX-801 , which might attract attention from investors interested in public health solutions. However, there are some risks. The stock has shown high volatility recently, with a 90.31% change over the last 10 days . Analyst ratings are mixed, with some suggesting a "Strong Sell" due to technical signals , while others have a "Buy" rating . The inclusion in the Russell indexes might bring in some buying pressure, but the stock's short-term technical indicators are showing a downtrend . I need to consider the market context. The Russell reconstitution happened on June 30, 2025, so passive funds would have adjusted their holdings by then. The upcoming FDA decision is the next major catalyst. If the FDA approves TNX-102 SL, the stock could surge. If not, there might be a sharp decline. The recent positive trial results might already be priced in, but the uncertainty around the FDA decision adds volatility. Looking at the price predictions, some sources suggest a potential decline , while others are more bullish . The average target price mentioned is around $70, which is a 76.80% upside from the current price . However, the short-term forecasts are more cautious, with a predicted range of $44.73 to $45.10 . I should also check the user's history. They previously asked about stock recommendations and price predictions, so they might be looking for a detailed analysis with both bullish and bearish factors. The user profile doesn't provide specific preferences, so I need to present a balanced view. Putting it all together, the prediction should consider the upcoming FDA decision, recent positive news, inclusion in Russell indexes, and technical indicators. The stock is likely to experience volatility, with a potential upside if the FDA approves the drug but risks of a pullback if there's any negative news or market reaction to the pending decision. ``` **Conclusion** 🎯 Based on the latest data and forecasts, **Tonix Pharmaceuticals (TNXP)** is projected to experience **moderate volatility** with a **mixed outlook** due to upcoming catalysts and technical pressures. Here's the breakdown: --- ### 📊 **Price Forecast for TNXP (July 19, 2025)** | Metric | Forecast (July 19, 2025) | |----------------------------|---------------------------| | **Price Range** | $44.73 - $45.10 | | **Expected Change** | -5.2% to -4.8% from July 18 closing price ($47.19) | | **Trend Outlook** | **Bearish** (50% continuation probability) | | **Key Catalyst** | FDA decision for TNX-102 SL (August 15, 2025) | --- ### 📊 **Analysis** 1. **Price Forecast** - The **Trend Similarity-Based Forecast** predicts a **mean price decline** to **$44.95** by July 19, 2025, with a **34% confidence interval** ranging from $44.73 to $45.10 . - The **Support and Resistance Channel-Based Forecast** confirms the stock is **trading near its short-term resistance level** ($47.19 - $49.00), with a **53.36% historical win rate** . 2. **Market Sentiment** - **Bullish Momentum**: Recent inclusion in the **Russell 2000 Index** (June 30, 2025) and positive Phase 3 trial results for TNX-102 SL could drive short-term resilience. - **Bearish Pressure**: High short-term volatility (90.31% price change over the last 10 days) and mixed analyst ratings (Buy vs. Strong Sell) suggest uncertainty. 3. **Risks** - **FDA Decision Risk**: The pending approval for TNX-102 SL (August 15, 2025) could trigger significant price swings. - **Competition**: Recent data on TNX-801 (mpox vaccine) may divert attention from the fibromyalgia drug. --- ### 📊 **Final Takeaway** **TNXP** is likely to **test the $44.73 - $45.10 range** tomorrow, with a **50% chance of continued downward movement** due to **short-term technical pressure** and **FDA-related uncertainty**. Investors should **brace for volatility** and monitor **FDA news** and **Russell index-related inflows** closely.